Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Equity (2020 - 2025)

Historic Return on Equity for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 0.16%.

  • Apellis Pharmaceuticals' Return on Equity rose 11600.0% to 0.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.16%, marking a year-over-year increase of 11600.0%. This contributed to the annual value of 0.94% for FY2024, which is 19700.0% up from last year.
  • As of Q3 2025, Apellis Pharmaceuticals' Return on Equity stood at 0.16%, which was up 11600.0% from 1.42% recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Return on Equity ranged from a high of 46.97% in Q3 2022 and a low of 10.56% during Q4 2021
  • For the 5-year period, Apellis Pharmaceuticals' Return on Equity averaged around 0.91%, with its median value being 1.73% (2023).
  • In the last 5 years, Apellis Pharmaceuticals' Return on Equity surged by 421600bps in 2022 and then plummeted by -490700bps in 2023.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Return on Equity stood at 10.56% in 2021, then soared by 74bps to 2.73% in 2022, then increased by 9bps to 2.48% in 2023, then skyrocketed by 66bps to 0.85% in 2024, then soared by 119bps to 0.16% in 2025.
  • Its last three reported values are 0.16% in Q3 2025, 1.42% for Q2 2025, and 1.14% during Q1 2025.